Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Americas Cancer Biologic Therapy Market

ID: MRFR/Pharma/0148-HCR
45 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Americas Cancer Biological Therapy market information, by type (Monoclonal Antibodies,  Gene Therapy, Colony-Stimulating Factors, Targeted Therapy and Others) by end users (hospitals & clinics, cancer research centers, laboratories) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Americas Cancer Biologic Therapy Market Infographic
Purchase Options
  1. 1 INTRODUCTION
    1. 1.1 DEFINITION
    2. 1.2 SCOPE OF STUDY
      1. 1.2.1 RESEARCH OBJECTIVE
      2. 1.2.2 ASSUMPTIONS & LIMITATIONS
        1. 1.2.2.1 ASSUMPTIONS
        2. 1.2.2.2 LIMITATIONS
    3. 1.3 MARKET STRUCTURE:
  2. 2 RESEARCH METHODOLOGY
    1. 2.1 RESEARCH PROCESS:
    2. 2.2 PRIMARY RESEARCH
    3. 2.3 SECONDARY RESEARCH:
  3. 3 MARKET DYNAMICS
    1. 3.1 DRIVERS
    2. 3.2 RESTRAINTS
    3. 3.3 OPPORTUNITIES
    4. 3.4 MACROECONOMIC INDICATORS
  4. 4 MARKET FACTOR ANALYSIS
    1. 4.1 PORTERS FIVE FORCES MODEL
    2. 4.2 BARGAINING POWER OF SUPPLIERS
    3. 4.3 BARGAINING POWER OF BUYERS
    4. 4.4 THREAT OF NEW ENTRANTS
    5. 4.5 THREAT OF SUBSTITUTES
    6. 4.6 INTENSITY OF RIVALRY
  5. 5 MARKET FACTOR ANALYSIS
    1. 5.1 PORTER’S FIVE FORCES MODEL
      1. 5.1.1 BARGAINING POWER OF SUPPLIERS
      2. 5.1.2 BARGAINING POWER OF BUYERS
      3. 5.1.3 THREAT OF NEW ENTRANTS
      4. 5.1.4 THREAT OF SUBSTITUTES
      5. 5.1.5 INTENSITY OF RIVALRY
    2. 5.2 SUPPLY CHAIN ANALYSIS
  6. 6 Americas Cancer Biologic Therapy Market, BY TYPES
    1. 6.1 MONOCLONAL ANTIBODIES
      1. 6.1.1 NAKED MONOCLONAL ANTIBODIES
      2. 6.1.2 CONJUGATED MONOCLONAL ANTIBODIES
      3. 6.1.3 OTHER
    2. 6.2 INTERFERONS
    3. 6.3 INTERLEUKINS
    4. 6.4 CANCER GROWTH INHIBITORS
      1. 6.4.1 TYROSINE KINASE INHIBITORS
      2. 6.4.2 MTOR INHIBITORS
      3. 6.4.3 PROTEASOME INHIBITORS
    5. 6.5 GENE THERAPY
    6. 6.6 COLONY-STIMULATING FACTORS
    7. 6.7 TARGETED THERAPY
    8. 6.8 CANCER VACCINES
    9. 6.8 OTHERS
  7. 7 Americas Cancer Biologic Therapy Market, BY END USER
    1. 7.1 HOSPITALS & CLINICS
    2. 7.2 CANCER RESEARCH CENTERS
    3. 7.3 LABORATORIES AND OTHERS
  8. 8 Americas Cancer Biologic Therapy Market, BY REGION
    1. 8.1 NORTH AMERICA
      1. 8.1.1 US
      2. 8.1.2 CANADA
      3. 8.1.3 REST OF AMERICA
  9. 9 COMPANY PROFILE
    1. 9.1 F. HOFFMANN-LA ROCHE AG
      1. 9.1.1 OVERVIEW
      2. 9.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
      3. 9.1.3 FINANCIAL UPDATES
      4. 9.1.4 KEY DEVELOPMENTS
    2. 9.2 NOVARTIS INTERNATIONAL AG
      1. 9.2.1 OVERVIEW
      2. 9.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
      3. 9.2.3 FINANCIAL UPDATES
      4. 9.2.4 KEY DEVELOPMENTS
    3. 9.3 ELI LILLY
      1. 9.3.1 OVERVIEW
      2. 9.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
      3. 9.3.3 FINANCIAL UPDATES
      4. 9.3.4 KEY DEVELOPMENTS
    4. 9.4 GSK
      1. 9.4.1 OVERVIEW
      2. 9.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
      3. 9.4.3 FINANCIAL UPDATES
      4. 9.4.4 KEY DEVELOPMENTS
    5. 9.5 MERCK & CO
      1. 9.5.1 OVERVIEW
      2. 9.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
      3. 9.5.3 FINANCIAL UPDATES
      4. 9.5.4 KEY DEVELOPMENTS
    6. 9.6 AMGEN INC
      1. 9.6.1 OVERVIEW
      2. 9.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
      3. 9.6.3 FINANCIAL UPDATES
      4. 9.6.4 KEY DEVELOPMENTS
    7. 9.7 OTHER

Americas Cancer Biological Therapy Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions